-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
Jazz Pharmaceuticals Completes Acquisition of Chimerix
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO
-
-
-
-
-
-
-
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Reports FDA Acceptance and Priority Review of Supplemental NDA for Xywav Oral Solution in Idiopathic Hypersomnia
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
-
15,472 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

